Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms

Johanna Abelsson, Björn Andréasson, Jan Samuelsson, Malin Hultcrantz, Elisabeth Ejerblad, Berit Johansson, Robyn Emanuel, Ruben Mesa, Peter Johansson

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The quality of life (QoL) at the time of diagnosis of myeloproliferative neoplasm (MPN) has, to date, not been studied. One hundred and seventy-nine patients with MPN: 80 with essential thrombocythemia (ET), 73 with polycythemia vera (PV), 22 with primary myelofibrosis (PMF) and four with MPN undifferentiated, were included in this study. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQC30) and the MPN-Symptom Assessment Form (MPN-SAF) were used to evaluate QoL. Fatigue was the most reported symptom in these patients. Patients with PV reported significantly higher mean scores for inactivity, dizziness, cough, itching, depression and lower total QoL compared to patients with ET. Patients with PV had significantly more headache and itching compared to patients with PMF. When the newly diagnosed patients with MPN were compared with a cohort of patients with MPN with mean disease duration of 7.8 years, the differences were most striking for patients with PMF, with significantly more fatigue, abdominal discomfort, concentration problems, insomnia, fever, weight loss and lower overall QoL developed over time.

Original languageEnglish (US)
Pages (from-to)2226-2230
Number of pages5
JournalLeukemia and Lymphoma
Volume54
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Polycythemia Vera
Quality of Life
Neoplasms
Primary Myelofibrosis
Essential Thrombocythemia
Pruritus
Fatigue
Symptom Assessment
Sleep Initiation and Maintenance Disorders
Dizziness
Cough
Headache
Weight Loss
Fever
Depression

Keywords

  • Essential thrombocythemia
  • Polycythemia vera
  • Primary myelofibrosis
  • Quality of life

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Abelsson, J., Andréasson, B., Samuelsson, J., Hultcrantz, M., Ejerblad, E., Johansson, B., ... Johansson, P. (2013). Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leukemia and Lymphoma, 54(10), 2226-2230. https://doi.org/10.3109/10428194.2013.766732

Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. / Abelsson, Johanna; Andréasson, Björn; Samuelsson, Jan; Hultcrantz, Malin; Ejerblad, Elisabeth; Johansson, Berit; Emanuel, Robyn; Mesa, Ruben; Johansson, Peter.

In: Leukemia and Lymphoma, Vol. 54, No. 10, 10.2013, p. 2226-2230.

Research output: Contribution to journalArticle

Abelsson, J, Andréasson, B, Samuelsson, J, Hultcrantz, M, Ejerblad, E, Johansson, B, Emanuel, R, Mesa, R & Johansson, P 2013, 'Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms', Leukemia and Lymphoma, vol. 54, no. 10, pp. 2226-2230. https://doi.org/10.3109/10428194.2013.766732
Abelsson, Johanna ; Andréasson, Björn ; Samuelsson, Jan ; Hultcrantz, Malin ; Ejerblad, Elisabeth ; Johansson, Berit ; Emanuel, Robyn ; Mesa, Ruben ; Johansson, Peter. / Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. In: Leukemia and Lymphoma. 2013 ; Vol. 54, No. 10. pp. 2226-2230.
@article{845e7d251964449b984948808d59fb6e,
title = "Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms",
abstract = "The quality of life (QoL) at the time of diagnosis of myeloproliferative neoplasm (MPN) has, to date, not been studied. One hundred and seventy-nine patients with MPN: 80 with essential thrombocythemia (ET), 73 with polycythemia vera (PV), 22 with primary myelofibrosis (PMF) and four with MPN undifferentiated, were included in this study. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQC30) and the MPN-Symptom Assessment Form (MPN-SAF) were used to evaluate QoL. Fatigue was the most reported symptom in these patients. Patients with PV reported significantly higher mean scores for inactivity, dizziness, cough, itching, depression and lower total QoL compared to patients with ET. Patients with PV had significantly more headache and itching compared to patients with PMF. When the newly diagnosed patients with MPN were compared with a cohort of patients with MPN with mean disease duration of 7.8 years, the differences were most striking for patients with PMF, with significantly more fatigue, abdominal discomfort, concentration problems, insomnia, fever, weight loss and lower overall QoL developed over time.",
keywords = "Essential thrombocythemia, Polycythemia vera, Primary myelofibrosis, Quality of life",
author = "Johanna Abelsson and Bj{\"o}rn Andr{\'e}asson and Jan Samuelsson and Malin Hultcrantz and Elisabeth Ejerblad and Berit Johansson and Robyn Emanuel and Ruben Mesa and Peter Johansson",
year = "2013",
month = "10",
doi = "10.3109/10428194.2013.766732",
language = "English (US)",
volume = "54",
pages = "2226--2230",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms

AU - Abelsson, Johanna

AU - Andréasson, Björn

AU - Samuelsson, Jan

AU - Hultcrantz, Malin

AU - Ejerblad, Elisabeth

AU - Johansson, Berit

AU - Emanuel, Robyn

AU - Mesa, Ruben

AU - Johansson, Peter

PY - 2013/10

Y1 - 2013/10

N2 - The quality of life (QoL) at the time of diagnosis of myeloproliferative neoplasm (MPN) has, to date, not been studied. One hundred and seventy-nine patients with MPN: 80 with essential thrombocythemia (ET), 73 with polycythemia vera (PV), 22 with primary myelofibrosis (PMF) and four with MPN undifferentiated, were included in this study. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQC30) and the MPN-Symptom Assessment Form (MPN-SAF) were used to evaluate QoL. Fatigue was the most reported symptom in these patients. Patients with PV reported significantly higher mean scores for inactivity, dizziness, cough, itching, depression and lower total QoL compared to patients with ET. Patients with PV had significantly more headache and itching compared to patients with PMF. When the newly diagnosed patients with MPN were compared with a cohort of patients with MPN with mean disease duration of 7.8 years, the differences were most striking for patients with PMF, with significantly more fatigue, abdominal discomfort, concentration problems, insomnia, fever, weight loss and lower overall QoL developed over time.

AB - The quality of life (QoL) at the time of diagnosis of myeloproliferative neoplasm (MPN) has, to date, not been studied. One hundred and seventy-nine patients with MPN: 80 with essential thrombocythemia (ET), 73 with polycythemia vera (PV), 22 with primary myelofibrosis (PMF) and four with MPN undifferentiated, were included in this study. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQC30) and the MPN-Symptom Assessment Form (MPN-SAF) were used to evaluate QoL. Fatigue was the most reported symptom in these patients. Patients with PV reported significantly higher mean scores for inactivity, dizziness, cough, itching, depression and lower total QoL compared to patients with ET. Patients with PV had significantly more headache and itching compared to patients with PMF. When the newly diagnosed patients with MPN were compared with a cohort of patients with MPN with mean disease duration of 7.8 years, the differences were most striking for patients with PMF, with significantly more fatigue, abdominal discomfort, concentration problems, insomnia, fever, weight loss and lower overall QoL developed over time.

KW - Essential thrombocythemia

KW - Polycythemia vera

KW - Primary myelofibrosis

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=84884492417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884492417&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.766732

DO - 10.3109/10428194.2013.766732

M3 - Article

C2 - 23398206

AN - SCOPUS:84884492417

VL - 54

SP - 2226

EP - 2230

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -